Five-Year Trial Shows Interferon Outperforms Hydroxyurea Molecularly in Myeloproliferative Neoplasms
The Danish DALIAH phase 3 trial found that low-dose pegylated interferon achieved superior long-term molecular responses to hydroxyurea in myeloproliferative ...
